TORONTO, May 20, 2021 /PRNewswire/ – Braxia Scientific Corp. (the «Company»), (CSE: BRAX) (OTC: SHRMF) (FWB: 496), a research driven clinical platform developing and providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce its common shares, previously listed for trading on the OTC Market in the United States under the symbol «SHRMF», are to commence trading on the OTC Market under the symbol «BRAXF» effective May 21, 2021.
The Company’s common shares will continue to trade on the Canadian Securities Exchange under the symbol «BRAX».
In May 2021, the Company announced its new name, Braxia Scientific Corp., to reflect its commitment to providing access to, and leadership in setting the standard of care for, ketamine treatment for depression through its network of clinics, as well as the Company’s ketamine and psychedelic derivative research and drug development priorities.
Braxia Scientific’s overarching aim is to shape the future of treatment for people suffering from depression and other mental health disorders.
About Braxia Scientific Corp.
Braxia Scientific is a research driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. The Company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. Braxia Scientific, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., currently operates multidisciplinary community-based clinics offering rapid-onset treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.
ON BEHALF OF THE BOARD
«Dr. Roger S. McIntyre«
Dr. Roger S. McIntyre
Chairman & CEO
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
Forward-looking Information Cautionary Statement
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are «forward-looking statements.» Forward-looking statements include statements about the intended promise of ketamine and esketamine-based treatments for depression, and the potential for ketamine to treat other emerging psychiatric disorders, for the Company to be a leader in this space and for the Company’s ability to grow its clinical network. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.
View original content to download multimedia:http://www.prnewswire.com/news-releases/braxia-scientific-announces-symbol-change-on-otc-markets-to-braxf-301296600.html
SOURCE Braxia Scientific Corp.